Selagine Inc. is dedicated to developing innovative therapeutics aimed at treating ocular surface diseases, particularly focusing on conditions like Dry Eye Disease (DED) and bacterial infections. Their lead product, SLG-100, is a clinical-stage therapeutic designed to address DED by shifting the treatment paradigm from solely targeting T-cell mediated inflammation to also neutralizing specific inflammatory proteins and autoantibodies associated with the disease. This biologic product comprises pooled human immune globulins that contain natural anti-cytokine antibodies, providing broad-spectrum anti-inflammatory actions. Preliminary clinical trials have shown that SLG-100 significantly reduces the signs and symptoms of DED without adverse effects, highlighting its potential as an effective prescription therapeutic in a market that currently lacks sufficient options.

In addition to SLG-100, Selagine is developing SLG-200, a novel ophthalmic antibiotic specifically formulated to combat bacterial infections, particularly those caused by resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). With a significant portion of MRSA strains showing resistance to existing antibiotics, SLG-200 is designed to be highly potent against both susceptible and resistant Gram-positive pathogens. Its exclusive formulation for topical ophthalmic use aims to minimize the development of resistance, addressing a critical unmet need in the market for effective antibiotic treatments in ophthalmology. This innovative approach positions Selagine as a key player in advancing therapeutic options for ocular health.

United States

SELAGINE, Inc. develops novel antibody-based biologic eye drops for treatment of immunological or inflammatory ocular surface diseases such as Dry Eye Disease, Sjögren’s syndrome and ocular Graft-versus-Host Disease.

Selagine

Company Details